Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected to be the takeover
Categories
Biotechnology
Lundbeck to acquire Alder BioPharmaceuticals for $1.95 billion; Alder stock hits new 52-week high
Denmark-based biopharma company Lundbeck announced today that it will acquire Alder BioPharmaceuticals (NASDAQ: ALDR) for $1.95 billion. Alder stock, which reached a
Catalyst Pharmaceuticals stock soars to record high
Catalyst Pharmaceuticals (NASDAQ: CPRX) stock soared to a record high of $7.67 on Wednesday as phase 3 trial results date is nearing
Earnings preview: Market has low expectations ahead of Advaxis’ Q3 report
Advaxis (NASDAQ: ADXS), a late-stage biotech firm, is one of the worst-performing healthcare stocks that continuously disappointed investors over the years. Though
Johnson & Johnson tumbles on rating downgrade, after opioid ruling
Johnson & Johnson (NYSE: JNJ) continued the slide Wednesday after suffering a big loss in the previous trading session as investor mood
Lannett stock jumps more than 15% after topping Q4 earnings and revenue estimates
Generic drug manufacturer Lannett's (NYSE: LCI) stock surged more than 15% after it reported Q4 earnings results. The company's bottom line and
Why Arbutus Biopharma stock dipped to 11-year low?
Arbutus Biopharma Corporation (NASDAQ: ABUS) stock plunged to an 11-year low of $1.31 on Monday due to considerable downside risk and unsatisfactory
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene's (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction.
Earnings preview: Will losses continue for Celsion in Q2
Celsion Corporation (NASDAQ: CLSN) is set to release its earnings results for the second quarter on Thursday before the market opens. The
Progenics posts wider-than-expected loss in Q2
Progenics Pharmaceuticals (NASDAQ: PGNX) reported a wider loss in the second quarter due to higher costs and expenses despite a jump in
What to look for when Progenics Pharma posts Q2 earnings
Progenics Pharmaceuticals (NASDAQ: PGNX) is set to release its earnings results for the second quarter of 2019 on Friday before the market
Alnylam Pharmaceuticals posts narrower-than-expected Q2 loss
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported a wider loss in the second quarter of 2019 due to higher costs and expenses. The bottom
Immunogen Inc (NASDAQ: IMGN) Q2 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q2 2019 earnings call dated Aug 02, 2019 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations Mark
Exelixis surpasses Q2 earnings estimate by 6 cents
Exelixis Inc. (NASDAQ: EXEL) reported second-quarter earnings of 29 cents per share, down 6.4% year-over-year. The bottom line surpassed the average analysts’
Amarin’s stock gains on Q2 results beat
Amarin Corporation plc (NASDAQ: AMRN) reported better-than-expected revenue and earnings for the second quarter of 2019, allowing the stock to gain 2.2%
BioTelemetry Q2 earnings exceed estimates on record revenues; stock up 10%
Medical technology company BioTelemetry, Inc. (NASDAQ: BEAT) reported higher earnings and revenues for the June quarter. Earnings topped expectations, while revenues came
Gilead’s Q2 results beat estimates
Gilead Sciences Inc. (NYSE: GILD) beat market estimates for revenue and earnings in the second quarter of 2019. Shares were down 0.21%
Amgen beats Q2 earnings and revenue estimates
Amgen Inc. (NASDAQ: AMGN) reported second quarter 2019 adjusted EPS of $3.97 on revenue of $5.9 billion. Analysts had predicted the biotechnology
Pfizer’s stock suffers as Q2 results and Mylan deal fail to impress Wall Street
Pfizer Inc.’s (NYSE: PFE) shares continue to trade in red after the company narrowly missed revenue estimates for the second quarter of
Celgene Q2 profit beats estimates, lifts FY19 guidance
Celgene Corporation (NASDAQ: CELG) reported a 50% jump in earnings for the second quarter of 2019 helped by higher revenue as well
Eli Lilly Q2 profit beats estimates, lifts FY19 forecast
Eli Lilly and Company (NYSE: LLY) swung to a profit in the second quarter of 2019 from a loss last year, helped